- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody | ||
| 20.02. | Ionis scraps early candidate for Alzheimer's in people with Down syndrome | ||
| 20.02. | Biohaven charts comeback path after FDA blow, placing bets on obesity | ||
| 20.02. | Daiichi picks former Novartis CMO John Tsai to head up R&D | ||
| 20.02. | Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch | ||
| 19.02. | Novartis winds down ph. 1 solid tumor program after lacking efficacy | ||
| 19.02. | White House frustration may have fueled FDA's Moderna walkback: Politico | ||
| 19.02. | J&J halts enrollment in phase 2 trial of AC Immune-partnered Alzheimer's therapy | ||
| 19.02. | Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study | ||
| 18.02. | Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal | ||
| 18.02. | Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug | ||
| 18.02. | Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal | ||
| 18.02. | FDA accepts filing for Moderna flu vaccine after swift rethink | ||
| 18.02. | Preclinical eye disease biotech sets sights on $17M NYSE IPO | ||
| 18.02. | Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study | ||
| 17.02. | Boehringer axes inhaled gene therapy after viewing cystic fibrosis data | ||
| 17.02. | Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering | ||
| 17.02. | Cyrano noses toward pivotal trial after midphase smell loss win | ||
| 17.02. | Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push | ||
| 17.02. | Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data | ||
| 13.02. | FDA rejects Disc's rare disease drug despite commissioner's voucher | ||
| 13.02. | 'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments | ||
| 13.02. | After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio | ||
| 13.02. | Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg | ||
| 13.02. | Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.